Skip to main content

Advertisement

SpringerLink
Log in

Kidney cancer

Finding a niche for girentuximab in metastatic renal cell carcinoma

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

For nearly two decades, carbonic anhydrase IX (CAIX) expression has been investigated as a prognostic marker in renal cell carcinoma (RCC). During this time, CAIX-directed treatments have emerged, including 177Lu-labelled girentuximab. A small phase II study highlights modest efficacy and a concerning safety profile associated with this compound in patients with metastatic RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Muselaers, C. H. et al. Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. 69, 767–770 (2016).

    Article  CAS  Google Scholar 

  2. Belldegrun, A. S. et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC — results and implications for adjuvant clinical trials [abstract]. J. Clin. Oncol. 31 (Suppl.), 4507 (2013).

    Google Scholar 

  3. Stillebroer, A. B. et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. 64, 478–485 (2013).

    Article  CAS  Google Scholar 

  4. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).

    Article  CAS  Google Scholar 

  5. Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015).

    Article  CAS  Google Scholar 

  6. Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015).

    Article  CAS  Google Scholar 

  7. van Kuijk, S. J. et al. Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis. Front. Oncol. 6, 69 (2016).

    Article  Google Scholar 

  8. Bui, M. H. T. et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802–811 (2003).

    CAS  PubMed  Google Scholar 

  9. McDermott, D. F. et al. The high-dose aldesleukin “Select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 21, 561–568 (2015).

    Article  CAS  Google Scholar 

  10. Stewart, G. D. et al. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur. Urol. 66, 956–963 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sumanta K. Pal is at the Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, California 91010, USA.,

    Sumanta K. Pal

  2. Neeraj Agarwal is at the Department of Medical Oncology, Huntsman Cancer Hospital, Clinic 2B GU, 1950 Circle of Hope, Salt Lake City, Utah 84112, USA.,

    Neeraj Agarwal

Authors
  1. Sumanta K. Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neeraj Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sumanta K. Pal.

Ethics declarations

Competing interests

S.K.P. receives honoraria from Astellas, Medivation and Novartis, and receives consulting fees from Astellas, Aveo, BMS, Exelixis, Genentech, GSK, Novartis and Pfizer. N.A. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pal, S., Agarwal, N. Finding a niche for girentuximab in metastatic renal cell carcinoma. Nat Rev Urol 13, 442–443 (2016). https://doi.org/10.1038/nrurol.2016.115

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.115

  • Springer Nature Limited

This article is cited by

Search

Navigation